Shayla E Russell1, Anna B Rachlin1, Karen L Smith1, John Muschamp1, Loren Berry2, Zhiyang Zhao2, Elena H Chartoff3. 1. Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont. 2. Department of Pharmacokinetics and Drug Metabolism, Amgen, Cambridge, Massachusetts. 3. Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont. Electronic address: echartoff@mclean.harvard.edu.
Abstract
BACKGROUND: Dynorphin, an endogenous ligand at kappa opioid receptors (KORs), produces depressive-like effects and contributes to addictive behavior in male nonhuman primates and rodents. Although comorbidity of depression and addiction is greater in women than men, the role of KORs in female motivated behavior is unknown. METHODS: In adult Sprague-Dawley rats, we used intracranial self-stimulation to measure effects of the KOR agonist (±)-trans-U-50488 methanesulfonate salt (U-50488) (.0-10.0 mg/kg) on brain stimulation reward in gonadally intact and castrated males and in females at estrous cycle stages associated with low and high estrogen levels. Pharmacokinetic studies of U-50488 in plasma and brain were conducted. Immunohistochemistry was used to identify sex-dependent expression of U-50488-induced c-Fos in brain. RESULTS: U-50488 dose-dependently increased the frequency of stimulation (threshold) required to maintain intracranial self-stimulation responding in male and female rats, a depressive-like effect. However, females were significantly less sensitive than males to the threshold-increasing effects of U-50488, independent of estrous cycle stage in females or gonadectomy in males. Although initial plasma concentrations of U-50488 were higher in females, there were no sex differences in brain concentrations. Sex differences in U-50488-induced c-Fos activation were observed in corticotropin releasing factor-containing neurons of the paraventricular nucleus of the hypothalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus of the stria terminalis. CONCLUSIONS: These data suggest that the role of KORs in motivated behavior of rats is sex-dependent, which has important ramifications for the study and treatment of mood-related disorders, including depression and drug addiction in people.
BACKGROUND: Dynorphin, an endogenous ligand at kappa opioid receptors (KORs), produces depressive-like effects and contributes to addictive behavior in male nonhuman primates and rodents. Although comorbidity of depression and addiction is greater in women than men, the role of KORs in female motivated behavior is unknown. METHODS: In adult Sprague-Dawley rats, we used intracranial self-stimulation to measure effects of the KOR agonist (±)-trans-U-50488 methanesulfonate salt (U-50488) (.0-10.0 mg/kg) on brain stimulation reward in gonadally intact and castrated males and in females at estrous cycle stages associated with low and high estrogen levels. Pharmacokinetic studies of U-50488 in plasma and brain were conducted. Immunohistochemistry was used to identify sex-dependent expression of U-50488-induced c-Fos in brain. RESULTS:U-50488 dose-dependently increased the frequency of stimulation (threshold) required to maintain intracranial self-stimulation responding in male and female rats, a depressive-like effect. However, females were significantly less sensitive than males to the threshold-increasing effects of U-50488, independent of estrous cycle stage in females or gonadectomy in males. Although initial plasma concentrations of U-50488 were higher in females, there were no sex differences in brain concentrations. Sex differences in U-50488-induced c-Fos activation were observed in corticotropin releasing factor-containing neurons of the paraventricular nucleus of the hypothalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus of the stria terminalis. CONCLUSIONS: These data suggest that the role of KORs in motivated behavior of rats is sex-dependent, which has important ramifications for the study and treatment of mood-related disorders, including depression and drug addiction in people.
Authors: U Arvidsson; M Riedl; S Chakrabarti; L Vulchanova; J H Lee; A H Nakano; X Lin; H H Loh; P Y Law; M W Wessendorf Journal: Proc Natl Acad Sci U S A Date: 1995-05-23 Impact factor: 11.205
Authors: W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler Journal: Science Date: 1998-12-18 Impact factor: 47.728
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon Journal: Biol Psychiatry Date: 2008-07-17 Impact factor: 13.382
Authors: Atul P Daiwile; Subramaniam Jayanthi; Bruce Ladenheim; Michael T McCoy; Christie Brannock; Jennifer Schroeder; Jean Lud Cadet Journal: Int J Neuropsychopharmacol Date: 2019-11-01 Impact factor: 5.176
Authors: Abigail R Laman-Maharg; Tiffany Copeland; Evelyn Ordoñes Sanchez; Katharine L Campi; Brian C Trainor Journal: Behav Brain Res Date: 2017-06-15 Impact factor: 3.332
Authors: Cindee F Robles; Marissa Z McMackin; Katharine L Campi; Ian E Doig; Elizabeth Y Takahashi; Michael C Pride; Brian C Trainor Journal: Behav Brain Res Date: 2014-01-18 Impact factor: 3.332
Authors: Rachel I Anderson; Marcelo F Lopez; William C Griffin; Harold L Haun; Daniel W Bloodgood; Dipanwita Pati; Kristen M Boyt; Thomas L Kash; Howard C Becker Journal: Neuropsychopharmacology Date: 2018-12-11 Impact factor: 7.853
Authors: Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin Journal: J Neurosci Date: 2018-08-03 Impact factor: 6.167